2Q Pharma Results Preview: Pfizer, Allergan, Teva, Merck KGaA & Shire
Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?
You may also be interested in...
AstraZeneca's CEO used the company's second-quarter earnings call to proclaim his commitment to the business just weeks after rumors spread worldwide that he might take up a vacant chief executive role at a rival firm.
Topline Phase III data for AstraZeneca's PD-L1 inhibitor Imfinzi in NSCLC have overshadowed the group's second quarter earnings – but not in a good way. Positive Tagrisso data from the Phase III FLAURA trial reported at the same time were not enough to stem the stock bleed.
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.